(Q39695495)

English

The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 September 2017

The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines (English)

1 reference

Europe PubMed Central

14 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Daniel R Budman

1

1 reference

Europe PubMed Central

14 September 2017

Julia Tai

2

1 reference

Europe PubMed Central

14 September 2017

Anthony Calabro

3

1 reference

Europe PubMed Central

14 September 2017

Veena John

4

1 reference

Europe PubMed Central

14 September 2017

publication date

9 June 2010

1 reference

Europe PubMed Central

14 September 2017

Investigational New Drugs

1 reference

Europe PubMed Central

14 September 2017

29

1 reference

Europe PubMed Central

14 September 2017

6

1 reference

Europe PubMed Central

14 September 2017

1224-1229

1 reference

Europe PubMed Central

14 September 2017

https://scigraph.springernature.com/pub.10.1007/s10637-010-9467-6

0 references

Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

The biology of ovarian cancer: new opportunities for translation

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

New therapeutic agents in ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Management of recurrent ovarian carcinoma: current status and future directions

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Anticancer activities of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

The aggresome pathway as a target for therapy in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Clinical studies of histone deacetylase inhibitors.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Preclinical versus clinical drug combination studies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Gene expression patterns in ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Classification of cancer cell lines using an automated two-dimensional liquid mapping method with hierarchical clustering techniques.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials?

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Drug combination studies and their synergy quantification using the Chou-Talalay method

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9467-6

21 January 2018

Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved

1 reference

https://pubmed.ncbi.nlm.nih.gov/20533074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Karyotypic complexity of the NCI-60 drug-screening panel.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20533074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The search for synergy: a critical review from a response surface perspective.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20533074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/20533074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative properties of five human ovarian adenocarcinoma cell lines.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20533074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20533074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-010-9467-6

1 reference

Europe PubMed Central

14 September 2017

1 reference

Europe PubMed Central

14 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39695495&oldid=2088898223"